The cost of ARVs
Prices are falling as a result of competition from generic
manufacturers, international advocacy, strong political will,
and corporate responsiveness. UNICEF currently procures 40
different ARV formulations from generic as well as originator
pharmaceutical manufacturers. Triple therapy (the combination
of three different ARVs) can cost as little as $156 per patient,
per year. Nevertheless, the ARV market is a complex one, and
difficult challenges remain: the cost in some countries can
be more than ten times higher. Because of this, UNICEF keeps
abreast of market developments and fosters close relationships
and discussions with suppliers.
UNICEF is a partner in the AIDS Medicines and Diagnostics
Service (AMDS). AMDS seeks to expand access to high quality,
effective treatment for HIV/AIDS, by facilitating the increased
supply of medicines, diagnostics and preventative supplies
in developing countries. In addition, every year together
with partners, UNICEF produces and disseminates the report
‘Sources and Prices of Selected Medicines and Diagnostics
for People Living with HIV/AIDS’, giving governments
and NGOs informed choices in the procurement of quality, affordable
ARVs and test kits.
|
Sources and Prices of Selected Medicines and Diagnostics
for People Living with HIV/AIDS